Skip to main content

Table 1 Comparison of mean absorbance level and mean antibody titers with standard deviation (SD) of anti-HPV16 and HPV18 antibodies between non-smokers and smokers by vaccination group

From: Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine – a pilot study

  HPV vaccine (n = 103) HAV vaccine (n = 113)
  Non-smokers (n = 55)* mean (±SD) Smokers (n = 48)* mean (±SD) p-value† Non-smokers (n = 49)* mean (±SD) Smokers (n = 64)* mean (±SD) p-value†
HPV16
Antibody absorbance
Baseline 0.12 (±0.08) 0.29 (±0.52) 0.2 0.21 (±0.43) 0.18 (±0.29 ) 0.9
Month 7 1.97 (±0.78) 1.88 (±0.73) 0.4 0.01 (±0.04) 0.01 (±0.02) 0.7
HPV18
Antibody absorbance
Baseline 0.07 (±0.06) 0.18 (±0.008) 0.1 0.1 (±0.08) 0.10 (±0.14) 0.8
Month 7 1.44 (±0.85) 1.36 (±0.76) 0.6 0.01(±0.03) 0.01 (±0.03) 0.7
  1. *Non-smokers (Cotinine <20 ng/ml) and smokers (cotinine > =20 ng/ml).
  2. p-value derived from Mann–Whitney test to evaluate mean absorbance difference between non-smokers and smokers.